|
Re: AHA 2018
|
1
|
Resverlogix Corp.
|
Nov 11, 2018 08:05AM
|
|
Re: AHA 2018
|
4
|
Resverlogix Corp.
|
Nov 10, 2018 10:13PM
|
|
Re: AHA 2018
|
4
|
Resverlogix Corp.
|
Nov 10, 2018 05:02PM
|
|
Re: Amarin / Mineral Oil
|
4
|
Resverlogix Corp.
|
Nov 10, 2018 04:11PM
|
|
Re: AHA 2018
|
1
|
Resverlogix Corp.
|
Nov 09, 2018 12:43PM
|
|
Re: Resverlogix H2 2018 events
|
1
|
Resverlogix Corp.
|
Nov 09, 2018 11:59AM
|
|
Re: Resverlogix H2 2018 events
|
|
Resverlogix Corp.
|
Nov 09, 2018 10:23AM
|
|
AHA 2018
|
3
|
Resverlogix Corp.
|
Nov 09, 2018 08:43AM
|
|
Re: Zacks SCR Resverlogix Report 11/5/18; Apabetalone: The Last Mile
|
7
|
Resverlogix Corp.
|
Nov 06, 2018 10:11PM
|
|
Re: Zacks SCR Resverlogix Report 11/5/18; Apabetalone: The Last Mile
|
2
|
Resverlogix Corp.
|
Nov 06, 2018 05:59PM
|
|
Zacks SCR Resverlogix Report 11/5/18; Apabetalone: The Last Mile
|
4
|
Resverlogix Corp.
|
Nov 06, 2018 04:51PM
|
|
Re: Researchers Successfully Treat Metastatic Cancer
|
3
|
Zenith Epigenetics
|
Nov 06, 2018 04:22PM
|
|
Re: Bio Europe presentation happening now
|
4
|
Resverlogix Corp.
|
Nov 06, 2018 11:57AM
|
|
Re: 3 point MACE in Phase 3 should be 10% percent lower than 4 point MACE in Phase 2's
|
3
|
Resverlogix Corp.
|
Nov 06, 2018 11:19AM
|
|
Re: 3 point MACE in Phase 3 should be 10% percent lower than 4 point MACE in Phase 2's
|
3
|
Resverlogix Corp.
|
Nov 06, 2018 11:09AM
|
|
BET proteins, NFkB and Diabetic Kidney Disease
|
7
|
Resverlogix Corp.
|
Nov 05, 2018 03:54PM
|
|
Re: BETonMACE baseline data
|
3
|
Resverlogix Corp.
|
Nov 05, 2018 03:19PM
|
|
Re: BETonMACE baseline data
|
4
|
Resverlogix Corp.
|
Nov 05, 2018 03:12PM
|
|
BIO-Europe tomorrow
|
2
|
Resverlogix Corp.
|
Nov 05, 2018 12:36PM
|
|
Re: BIO Europe
|
3
|
Zenith Epigenetics
|
Nov 05, 2018 12:32PM
|
